Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adial Pharmaceuticals, Inc. (ADIL)
USD2.72
+0.07 (+2.64%)
US NASDAQ Healthcare Biotechnology
Address
1180 Seminole Trail 22901
Charlottesville, VA, US
Charlottesville, VA, US
CEO
Cary John Claiborne
Website
adialpharma.com
IPO
2018-07-27
CIK 1513525 ISIN US00688A3041
Also trades on
NASDAQ Capital Market · ADIL (USD)
NASDAQ Capital Market · ADILW (USD)
Description
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.72
+0.07 (+2.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
479.1K
Beta
1.46
Float Shares
954.9K
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.70% | -10.56% | -8.28% | -49.47% | -82.55% | -73.82% | -90.56% | -99.23% | -99.89% | -99.94% | -99.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
2.72
Low
8.00
+194.1%
Consensus
8.00
+194.1%
Median
8.00
+194.1%
High
8.00
+194.1%
DCF (Unlevered)
7.96
+192.7%
DCF (Levered)
8.80
+223.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
8.00
+194.1%
|
| Last Year | 1 |
8.00
+194.1%
|
| All Time | 1 |
8.00
+194.1%
|
Quality scores
Altman Z-Score
-28.09
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+32.8% ★ Q1'26: +82.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +923.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-10.1% ★ Q1'26: +84.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 23.19M (-100.0%)
|
46.00M
46.00M – 46.00M
+98.4% YoY
|
4.40M
4.40M – 4.40M
-90.4% YoY
|
47.00M
47.00M – 47.00M
+968.2% YoY
|
96.00M
96.00M – 96.00M
+104.3% YoY
|
48.87M
48.87M – 48.87M
-49.1% YoY
|
| EBITDA |
-8.28M
|
-7.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-8.28M
|
-7.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-13.20M
est: -51.58M (+74.4%)
|
-7.98M
est: -7.98M (+0.0%)
|
-4.09M
-4.09M – -4.09M
+48.7% YoY
|
-1.73M
-1.73M – -1.73M
+57.6% YoY
|
-1.12M
-1.12M – -1.12M
+35.5% YoY
|
-1.24M
-1.24M – -1.24M
-10.8% YoY
|
320.9K
320.9K – 320.9K
+125.9% YoY
|
| SGA |
5.06M
|
5.18M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-17.75
est: -69.38 (+74.4%)
|
-11.93
est: -11.11 (-7.4%)
|
-6.12
-6.12 – -6.12
+44.9% YoY
|
-2.59
-2.59 – -2.59
+57.6% YoY
|
-1.67
-1.67 – -1.67
+35.5% YoY
|
-1.85
-1.85 – -1.85
-10.8% YoY
|
0.48
0.48 – 0.48
+125.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
1.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bankole A. Johnson | 1.51M | 22.30% | 488.1K | 1.02M | 488.1K | 1.02M | IN | United States of America | 2018-11-14 | ↗ |
| 2 | Schuyler | 1.45M | 19.18% | 888.3K | 558.2K | 888.3K | 558.2K | IN | States of America | 2018-11-14 | ↗ |
| 3 | William B. Stilley, III | 934.2K | 13.65% | 792.3K | 142.0K | 792.3K | 142.0K | IN | United States of America | 2018-11-14 | ↗ |
| 4 | Howard Peikin | 904.4K | 4.40% | 904.4K | — | 904.4K | — | IN | States | 2022-02-14 | ↗ |
| 5 | En Fidecomiso de Mi Vida 11/23/2010 (Trust) | 850.9K | 13.00% | — | 850.9K | — | 850.9K | OO | Trust formed under the laws of the State of Texas | 2018-11-14 | ↗ |
| 6 | Empery Asset Management, LP | 716.3K | 9.84% | — | 716.3K | — | — | PN | Delaware | 2019-03-01 | ↗ |
| 7 | Martin D. Hoe | 716.3K | 9.84% | — | 716.3K | — | — | IN | United States | 2019-03-01 | ↗ |
| 8 | Ryan M. Lane | 716.3K | 9.84% | — | 716.3K | — | — | IN | United States | 2019-03-01 | ↗ |
| 9 | Armistice Capital Master Fund Ltd. | 712.5K | 5.00% | — | 712.5K | — | 712.5K | CO | Delaware | 2020-06-19 | ↗ |
| 10 | W. Newman, Jr. | 683.1K | 9.78% | 22.8K | 660.3K | 22.8K | 660.3K | IN | States of America | 2018-11-14 | ↗ |
| 11 | Empery Tax Efficient II, LP | 676.1K | 4.99% | — | 791.3K | — | 791.3K | PN | Delaware | 2020-01-21 | ↗ |
| 12 | 151 Investors, LLC | 552.0K | 8.50% | — | 552.0K | — | 552.0K | OO | liability company formed under the laws of the State of Virginia | 2018-11-14 | ↗ |
| 13 | Ventures, LLC | 478.5K | 6.96% | — | 478.5K | — | 478.5K | OO | liability company formed under the laws of the State of Virginia | 2018-11-14 | ↗ |
| 14 | Intracoastal Capital LLC | 470.0K | 3.40% | — | 470.0K | — | 470.0K | OO | United States America | 2020-06-18 | ↗ |
| 15 | Armistice Capital, LLC | 167.0K | 9.99% | — | 167.0K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 16 | Steven Boyd | 167.0K | 9.99% | — | 167.0K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
-19 vs prev Q
New positions
0
Closed positions
19
Increased
0
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 2.55M +2.6M (+100.0%) | 562.0K +562.0K (+100.0%) | 11.52% +11.521 pp | 0.01% +0.007 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 2 | CITADEL ADVISORS LLC | 219.6K +75.8K (+52.7%) | 48.3K -2.5K (-4.9%) | 0.99% +0.342 pp | 0.00% +0.000 pp | USD0.35 +1,471.4% | 2 qtrs — |
| 3 | VANGUARD GROUP INC | 156.0K +— (+0.0%) | 34.3K -20.9K (-37.9%) | 0.70% +0.000 pp | 0.00% +0.000 pp | USD0.38 +1,347.4% | 4 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 155.7K -8.4K (-5.1%) | 34.3K -23.8K (-40.9%) | 0.70% -0.038 pp | 0.00% +0.000 pp | USD0.62 +787.1% | 7 qtrs — |
| 5 | JANE STREET GROUP, LLC | 121.8K +109.5K (+887.3%) | 26.8K +22.4K (+514.4%) | 0.55% +0.494 pp | 0.00% +0.000 pp | USD0.23 -4.3% | 3 qtrs — |
| 6 | NORTHERN TRUST CORP | 66.0K +66.0K (+100.0%) | 14.5K +14.5K (+100.0%) | 0.30% +0.298 pp | 0.00% +0.000 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 7 | VIRTU FINANCIAL LLC | 63.8K +63.8K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.29% +0.288 pp | 0.00% +0.001 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 8 | XTX TOPCO LTD | 52.1K +52.1K (+100.0%) | 11.5K +11.5K (+100.0%) | 0.24% +0.235 pp | 0.00% +0.000 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 9 | MANCHESTER CAPITAL MANAGEMENT LLC | 48.1K +— (+0.0%) | 10.6K -6.4K (-37.8%) | 0.22% +0.000 pp | 0.00% -0.001 pp | USD2.78 -92.1% | 10 qtrs — |
| 10 | BLACKROCK, INC. | 27.8K +— (+0.0%) | 6.1K -3.7K (-37.8%) | 0.13% +0.000 pp | 0.00% +0.000 pp | USD1.00 +450.0% | 6 qtrs — |
| 11 | STONEX GROUP INC. | 19.5K +19.5K (+100.0%) | 4.3K +4.3K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.000 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 12 | TWO SIGMA SECURITIES, LLC | 17.1K +4.2K (+33.0%) | 3.8K -783.0 (-17.3%) | 0.08% +0.019 pp | 0.00% 0.000 pp | USD0.35 +1,471.4% | 2 qtrs — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.1K +12.1K (+100.0%) | 2.7K +2.7K (+100.0%) | 0.05% +0.055 pp | 0.00% +0.000 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 14 | PRIVATE MANAGEMENT GROUP INC | 10.0K +— (+0.0%) | 2.2K -1.3K (-37.8%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD0.35 -37.1% | 2 qtrs — |
| 15 | UBS GROUP AG | 9.2K -9.6K (-51.1%) | 2.0K -4.6K (-69.5%) | 0.04% -0.043 pp | 0.00% +0.000 pp | USD0.65 +746.2% | 10 qtrs — |
| 16 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.3K -29.0 (-2.1%) | 295.00 -189.0 (-39.0%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.10 -80.0% | 9 qtrs — |
| 17 | SBI SECURITIES CO., LTD. | 1.2K -238.0 (-17.0%) | 255.00 -238.0 (-48.3%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD0.76 +623.7% | 5 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 205.00 +23.0 (+12.6%) | 45.00 -19.0 (-29.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.49 +1,022.4% | 7 qtrs — |
| 19 | WELLS FARGO & COMPANY/MN | 160.00 +— (+0.0%) | 35.00 -22.0 (-38.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.94 +485.1% | 5 qtrs — |
| 20 | HARBOUR INVESTMENTS, INC. | 99.00 +99.0 (+100.0%) | 22.00 +22.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.21 +4.8% | 1 qtrs NEW |
| 21 | ABOUND WEALTH MANAGEMENT | 27.00 +— (+0.0%) | 6.00 -4.0 (-40.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.78 -92.1% | 10 qtrs — |
| 22 | MORGAN STANLEY | 9.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 10 qtrs — |
| 23 | HRT FINANCIAL LP | — -11.2K (-100.0%) | — -3.0K (-100.0%) | 0.00% -0.051 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 843.30 | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
390.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+390,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-07 | Shah Vinay | Officer | A-Award | A | Common Stock | 17,325 | 0.00 | — | 17,325 | D | ↗ |
| 2026-04-07 | Schuyler Kevin | Director | A-Award | A | Common Stock | 9,185 | 0.00 | — | 9,213 | D | ↗ |
| 2026-04-07 | Goodman Tony | Director / Officer | A-Award | A | Common Stock | 26,510 | 0.00 | — | 26,523 | D | ↗ |
| 2026-04-07 | Gilliland Robertson H. | Director | A-Award | A | Common Stock | 9,185 | 0.00 | — | 9,185 | D | ↗ |
| 2026-04-07 | Claiborne Cary J | Director / Officer | A-Award | A | Common Stock | 37,985 | 0.00 | — | 40,417 | D | ↗ |
| 2026-04-07 | Anderson J. Kermit | Director | A-Award | A | Stock Option (Right to Buy) | 9,185 | 1.64 | 15.1K | 9,185 | D | ↗ |
| 2025-05-29 | Shah Vinay | Officer | A-Award | A | Stock Option (Right to Buy) | 9,000 | 0.69 | 6.2K | 9,000 | D | ↗ |
| 2025-05-29 | Schuyler Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 0.69 | 19.3K | 28,000 | D | ↗ |
| 2025-05-29 | Newman James W. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 0.69 | 19.3K | 28,000 | D | ↗ |
| 2025-05-29 | Goodman Tony | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 94,000 | 0.69 | 64.7K | 94,000 | D | ↗ |
| 2025-05-29 | Gilliland Robertson H. | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 0.69 | 19.3K | 28,000 | D | ↗ |
| 2025-05-29 | Claiborne Cary J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 138,000 | 0.69 | 94.9K | 138,000 | D | ↗ |
| 2025-05-29 | Anderson J. Kermit | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 0.69 | 19.3K | 28,000 | D | ↗ |
| 2024-12-05 | Claiborne Cary J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 1.15 | 402.5K | 350,000 | D | ↗ |
| 2024-11-16 | Shah Vinay | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-25 | Truluck Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.35 | 33.8K | 25,000 | — | ↗ |
| 2024-03-25 | Schuyler Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 1.35 | 16.2K | 12,000 | — | ↗ |
| 2024-03-25 | Newman James W. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 1.35 | 16.2K | 12,000 | — | ↗ |
| 2024-03-25 | Goodman Tony | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 42,000 | 1.35 | 56.7K | 42,000 | — | ↗ |
| 2024-03-25 | Gilliland Robertson H. | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 1.35 | 16.2K | 12,000 | — | ↗ |
| 2024-03-25 | Claiborne Cary J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 1.35 | 81.0K | 60,000 | — | ↗ |
| 2024-03-25 | Anderson J. Kermit | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 1.35 | 16.2K | 12,000 | — | ↗ |
| 2023-09-29 | Schuyler Kevin | Director | P-Purchase | A | Common Stock | 700 | 2.74 | 1.9K | 700 | — | ↗ |
| 2023-05-23 | Truluck Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.30 | 37.8K | 125,000 | — | ↗ |
| 2023-05-23 | Stilley William B. III | Director | A-Award | A | Common Stock | 240,800 | 0.00 | — | 1,261,779 | — | ↗ |
| 2023-05-23 | Schuyler Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.30 | 15.1K | 50,000 | — | ↗ |
| 2023-05-23 | Newman James W. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.30 | 15.1K | 50,000 | — | ↗ |
| 2023-05-23 | Johnson Bankole A. | Director | A-Award | A | Stock Option | 40,000 | 0.30 | 12.1K | 40,000 | — | ↗ |
| 2023-05-23 | Goodman Tony | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.30 | 15.1K | 50,000 | — | ↗ |
| 2023-05-23 | Gilliland Robertson H. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.30 | 15.1K | 50,000 | — | ↗ |
| 2023-05-23 | Claiborne Cary J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.30 | 90.8K | 300,000 | — | ↗ |
| 2023-05-23 | Anderson J. Kermit | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.30 | 15.1K | 50,000 | — | ↗ |
| 2022-12-30 | Stilley William B. III | Director | D-Return | D | Common Stock | 166,667 | 0.00 | — | 1,020,979 | — | ↗ |
| 2022-09-20 | Claiborne Cary J | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.42 | 31.5K | 1,100,000 | — | ↗ |
| 2022-09-19 | Claiborne Cary J | Director / Officer | A-Award | A | Common Stock | 25,000 | 0.43 | 10.7K | 1,025,000 | — | ↗ |
| 2022-08-22 | Stilley William B. III | Director | A-Award | A | Stock Options | 100,000 | 0.56 | 55.5K | 100,000 | — | ↗ |
| 2022-08-18 | Claiborne Cary J | Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2022-06-27 | Goodman Tony | Director | A-Award | A | Stock Option | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-02-23 | Truluck Joseph | Officer | A-Award | A | Employee Stock Option | 100,000 | 2.00 | 200.0K | 100,000 | — | ↗ |
| 2022-02-23 | Stilley William B. III | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,187,646 | — | ↗ |
| 2022-02-23 | Schuyler Kevin | Director | A-Award | A | Stock Option | 40,000 | 2.00 | 80.0K | 40,000 | — | ↗ |
| 2022-02-23 | Newman James W. Jr. | Director | A-Award | A | Stock Option | 40,000 | 2.00 | 80.0K | 40,000 | — | ↗ |
| 2022-02-23 | Johnson Bankole A. | Officer | A-Award | A | Employee Stock Option | 35,000 | 2.00 | 70.0K | 35,000 | — | ↗ |
| 2022-02-23 | Goodman Tony | Director | A-Award | A | Stock Option | 40,000 | 2.00 | 80.0K | 40,000 | — | ↗ |
| 2022-02-23 | Gilliland Robertson H. | Director | A-Award | A | Stock Option | 40,000 | 2.00 | 80.0K | 40,000 | — | ↗ |
| 2022-02-23 | Claiborne Cary J | Officer | A-Award | A | Employee Stock Option | 6,667 | 2.00 | 13.3K | 6,667 | — | ↗ |
| 2022-02-23 | Anderson J. Kermit | Director | A-Award | A | Stock Option | 40,000 | 2.00 | 80.0K | 40,000 | — | ↗ |
| 2021-12-30 | Newman James W. Jr. | Director | P-Purchase | A | Common Stock | 10,000 | 2.71 | 27.1K | 34,644 | — | ↗ |
| 2021-12-23 | Schuyler Kevin | Director / 10% Owner | G-Gift | D | Common Stock | 312,990 | 0.00 | — | 0 | — | ↗ |
| 2021-12-07 | Claiborne Cary J | Director / Officer | A-Award | A | Stock options | 130,000 | 2.77 | 360.1K | 130,000 | — | ↗ |
| 2021-11-30 | Stilley William B. III | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,600 | 2.75 | 29.2K | 937,646 | — | ↗ |
| 2021-11-29 | Stilley William B. III | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 2.59 | 25.9K | 927,046 | — | ↗ |
| 2021-11-26 | Newman James W. Jr. | Director | P-Purchase | A | Common Stock | 10,000 | 2.85 | 28.5K | 34,475 | — | ↗ |
| 2021-11-02 | Claiborne Cary J | Director | A-Award | A | Stock Option | 60,000 | 3.15 | 189.0K | 60,000 | — | ↗ |
| 2021-10-04 | Johnson Bankole A. | Officer | S-Sale | D | Common Stock | 200,000 | 200,000.00 | 40.00B | 148,246 | — | ↗ |
| 2021-04-06 | Johnson Bankole A. | Officer | S-Sale | D | Common Stock | 150,000 | 2.50 | 375.0K | 548,336 | — | ↗ |
| 2021-02-08 | Truluck Joseph | Officer | A-Award | A | Employee Stock Option | 125,000 | 3.11 | 388.8K | 125,000 | — | ↗ |
| 2021-02-08 | Stilley William B. III | Director / Officer | A-Award | A | Employee Stock Option | 250,000 | 3.11 | 777.5K | 250,000 | — | ↗ |
| 2021-02-08 | Schuyler Kevin | Director | A-Award | A | Stock Option | 40,000 | 3.11 | 124.4K | 40,000 | — | ↗ |
| 2021-02-08 | Newman James W. Jr. | Director | A-Award | A | Stock Option | 40,000 | 3.11 | 124.4K | 40,000 | — | ↗ |
| 2021-02-08 | Goodman Tony | Director | A-Award | A | Stock Option | 40,000 | 3.11 | 124.4K | 40,000 | — | ↗ |
| 2021-02-08 | Gilliland Robertson H. | Director | A-Award | A | Stock Option | 40,000 | 3.11 | 124.4K | 40,000 | — | ↗ |
| 2021-02-08 | Anderson J. Kermit | Director | A-Award | A | Stock Option | 40,000 | 3.11 | 124.4K | 40,000 | — | ↗ |
| 2021-01-26 | Stilley William B. III | Director / Officer / 10% Owner | A-Award | A | Common Stock | 201,109 | 0.00 | — | 917,046 | — | ↗ |
| 2021-01-26 | Newman James W. Jr. | Director | A-Award | A | Common Stock | 2,544 | 0.00 | — | 152,963 | — | ↗ |
| 2020-11-23 | Schuyler Kevin | Director | G-Gift | D | Warrant to purchase common stock | 89,600 | 5.00 | 448.0K | 0 | — | ↗ |
| 2020-08-20 | Johnson Bankole A. | Officer | S-Sale | D | Common Stock | 350,000 | 1.21 | 423.5K | 1,055 | — | ↗ |
| 2020-05-19 | REICH JACK W | Director | A-Award | A | Stock Option | 90,000 | 1.47 | 132.3K | 90,000 | — | ↗ |
| 2020-03-27 | Newman James W. Jr. | Director | P-Purchase | A | Common Stock | 5,000 | 1.42 | 7.1K | 15,000 | — | ↗ |
| 2020-03-26 | Stilley William B. III | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 12,652 | 1.47 | 18.6K | 715,937 | — | ↗ |
| 2020-03-25 | Stilley William B. III | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 12,348 | 1.13 | 14.0K | 703,285 | — | ↗ |
| 2020-03-03 | Truluck Joseph | Director / Officer | A-Award | A | Employee Stock Option | 20,000 | 1.44 | 28.8K | 200,000 | — | ↗ |
| 2020-03-03 | Stilley William B. III | Director / Officer / 10% Owner | A-Award | A | Common stock | 54,167 | 0.00 | — | 690,937 | — | ↗ |
| 2020-03-03 | Schuyler Kevin | Director / 10% Owner | A-Award | A | Stock Option | 60,000 | 1.44 | 86.4K | 60,000 | — | ↗ |
| 2020-03-03 | Newman James W. Jr. | Director | A-Award | A | Stock Option | 60,000 | 1.44 | 86.4K | 60,000 | — | ↗ |
| 2020-03-03 | Goodman Tony | Director | A-Award | A | Stock Option | 60,000 | 1.44 | 86.4K | 60,000 | — | ↗ |
| 2020-03-03 | Gilliland Robertson H. | Director | A-Award | A | Stock Option | 60,000 | 1.44 | 86.4K | 60,000 | — | ↗ |
| 2020-03-03 | Anderson J. Kermit | Director | A-Award | A | Stock Option | 60,000 | 1.44 | 86.4K | 60,000 | — | ↗ |
| 2019-12-12 | Johnson Bankole A. | Officer / 10% Owner | S-Sale | D | Common Stock | 150,000 | 1.00 | 150.0K | 698,336 | — | ↗ |
| 2019-10-02 | Johnson Bankole A. | Officer / 10% Owner | A-Award | A | Common Stock | 3,187 | 0.00 | — | 351,055 | — | ↗ |
| 2019-03-29 | Johnson Bankole A. | Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 3.47 | 8.7K | 347,268 | — | ↗ |
| 2019-03-28 | Johnson Bankole A. | Officer / 10% Owner | P-Purchase | A | Common Stock | 40,000 | 3.15 | 125.8K | 314,768 | — | ↗ |
| 2019-03-24 | Johnson Bankole A. | Officer / 10% Owner | A-Award | A | Stock Option | 250,000 | 3.01 | 752.5K | 250,000 | — | ↗ |
| 2019-03-10 | Truluck Joseph | Officer | A-Award | A | Stock Option | 180,000 | 3.39 | 610.2K | 180,000 | — | ↗ |
| 2019-03-10 | Stilley William B. III | Director / Officer / 10% Owner | A-Award | A | Stock Option | 500,000 | 3.39 | 1.70M | 500,000 | — | ↗ |
| 2018-11-12 | Stilley William B. III | Director / Officer / 10% Owner | J-Other | A | Warrant to purchase common stock | 36,800 | 6.25 | 230.0K | 36,800 | — | ↗ |
| 2018-11-12 | Schuyler Kevin | Director / 10% Owner | J-Other | A | Warrant to purchase common stock | 192,600 | 6.25 | 1.20M | 192,600 | — | ↗ |
| 2018-11-12 | Newman James W. Jr. | Director | J-Other | A | Warrant to purchase common stock | 20,000 | 5.00 | 100.0K | 20,000 | — | ↗ |
| 2018-11-12 | Johnson Bankole A. | Director / 10% Owner | J-Other | D | Warrant to purchase units | 17,600 | 5.00 | 88.0K | 0 | — | ↗ |
| 2018-07-31 | Truluck Joseph | Officer | C-Conversion | A | Common Stock | 5,927 | 1,980.00 | 11.74M | 80,555 | — | ↗ |
| 2018-07-31 | Stilley William B. III | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 80,000 | 5.00 | 400.0K | 504,000 | — | ↗ |
| 2018-07-31 | Schuyler Kevin | Director | J-Other | A | Warrant to purchase common stock | 120,000 | 6.25 | 750.0K | 202,461 | — | ↗ |
| 2018-07-31 | Newman James W. Jr. | Director | P-Purchase | A | Warrant to purchase common stock | 10,000 | 6.25 | 62.5K | 102,000 | — | ↗ |
| 2018-07-31 | Johnson Bankole A. | Director / 10% Owner | A-Award | A | Common Stock | 40,382 | 0.00 | — | 313,750 | — | ↗ |
| 2018-07-31 | Goodman Tony | Director | P-Purchase | A | Warrant to purchase common stock | 7,000 | 6.25 | 43.8K | 7,000 | — | ↗ |
| 2018-07-31 | Gilliland Robertson H. | Director | C-Conversion | D | Convertible Note | 29,931 | 0.44 | 13.2K | 0 | — | ↗ |
| 2018-07-26 | Truluck Joseph | Officer | — | D | Convertible Note | 5,927 | 0.44 | 2.6K | 0 | — | ↗ |
| 2018-07-26 | Stilley William B. III | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 335,602 | — | ↗ |
| 2018-07-26 | Schuyler Kevin | Director | — | D | Convertible Note | 82,461 | 0.44 | 36.3K | 0 | — | ↗ |
| 2018-07-26 | Newman James W. Jr. | Director | — | I | Common Stock | 0 | 0.00 | — | 11,229 | — | ↗ |
| 2018-07-26 | Johnson Bankole A. | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 93,000 | — | ↗ |
| 2018-07-26 | Goodman Tony | Director | — | D | Common Stock | 0 | 0.00 | — | 1,755 | — | ↗ |
| 2018-07-26 | Gilliland Robertson H. | Director | — | I | Common Stock | 0 | 0.00 | — | 65,493 | — | ↗ |
| 2018-01-01 | Truluck Joseph | Officer | — | D | Stock Option | 30,132 | 5.70 | 171.8K | 0 | — | ↗ |
| 2018-01-01 | Stilley William B. III | Director / Officer / 10% Owner | — | D | Stock Option | 5,580 | 5.70 | 31.8K | 0 | — | ↗ |
| 2018-01-01 | Schuyler Kevin | Director | — | D | Stock Option | 5,580 | 5.70 | 31.8K | 0 | — | ↗ |
| 2018-01-01 | Newman James W. Jr. | Director | — | D | Stock Option | 5,580 | 5.70 | 31.8K | 0 | — | ↗ |
| 2018-01-01 | Johnson Bankole A. | Director / 10% Owner | — | D | Stock Option | 5,580 | 5.70 | 31.8K | 0 | — | ↗ |
| 2018-01-01 | Goodman Tony | Director | — | D | Stock Option | 11,160 | 5.70 | 63.6K | 0 | — | ↗ |
| 2018-01-01 | Gilliland Robertson H. | Director | — | D | Stock Option | 5,580 | 5.70 | 31.8K | 0 | — | ↗ |
| 2018-01-01 | Anderson J. Kermit | Director | — | D | Stock Option | 5,580 | 5.70 | 31.8K | 0 | — | ↗ |
| 2017-10-10 | Stilley William B. III | Director / Officer / 10% Owner | — | D | Warrant | 5,452 | 7.63 | 41.6K | 0 | — | ↗ |
| 2017-10-10 | Schuyler Kevin | Director | — | I | Warrant | 1,963 | 0.01 | 10.60 | 0 | — | ↗ |
| 2017-10-10 | Newman James W. Jr. | Director | — | I | Warrant | 1,186 | 7.63 | 9.0K | 0 | — | ↗ |
| 2017-10-10 | Johnson Bankole A. | Director / 10% Owner | — | D | Warrant | 3,275 | 7.63 | 25.0K | 0 | — | ↗ |
| 2017-10-10 | Gilliland Robertson H. | Director | — | I | Warrants | 65,493 | 7.63 | 499.7K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
959.6K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Cary Claiborne Chief Executive Officer and Member of the Board of Directors | 465.6K | 190.0K | 73.3K | — | — | 72.7K | 801.6K | 9.15% | ↗ |
| 2 | 2023 | Bankole A. Johnson Former Chief Medical Officer | 435.0K | — | — | — | — | — | 435.0K | 0.00% | ↗ |
| 3 | 2023 | Joseph A. M. Truluck Chief Financial Officer | 276.3K | 70.0K | 30.5K | — | — | 12.2K | 389.0K | 7.85% | ↗ |
| 4 | 2022 | Cary Claiborne Chief Executive Officer and Member of the Board of Directors | 356.7K | 181.1K | 600.9K | — | — | 58.4K | 1.20M | 50.20% | ↗ |
| 5 | 2022 | Joseph A. M. Truluck Chief Financial Officer | 267.5K | 67.9K | 162.9K | — | — | 12.2K | 510.5K | 31.91% | ↗ |
| 6 | 2022 | Bankole A. Johnson Former Chief Medical Officer | 416.2K | — | 57.0K | — | — | 16.2K | 489.4K | 11.65% | ↗ |
| 7 | 2018 | William B. Stilley Chief Executive Officer and Member of the board of directors | 180.8K | — | 988.4K | — | — | 42.5K | 1.21M | 81.57% | ↗ |
| 8 | 2018 | Joseph A. M. Truluck Chief Operating Officer and Chief Financial Officer | 85.2K | — | 223.2K | — | — | — | 308.4K | 72.38% | ↗ |
| 9 | 2017 | William B. Stilley Chief Executive Officer and Member of the board of directors | 60.0K | — | 276.7K | — | — | 28.4K | 365.0K | 75.79% | ↗ |
| 10 | 2017 | Joseph A. M. Truluck Chief Operating Officer and Chief Financial Officer | 26.4K | — | 145.0K | — | — | 723.00 | 172.2K | 84.25% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cary John Claiborne | Chief Executive Officer, President & Director | 810.1K | male |
| Vinay Shah | Chief Financial Officer & Treasurer | 453.6K | male |
| Tony Goodman | Chief Operating Officer & Director | 415.1K | male |
| Andrew Taubman | Vice President of Corporate Development | — | male |
| Brigitte Robertson | Acting Chief Medical Officer | — | — |
| Abel Svitavsky | Controller | — | male |
| John R. Martin | Chief Legal Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADIL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
